Le Lézard
Classified in: Health
Subjects: NPT, SVY, PSF

Skin Cancer Rates In Massachusetts Among Highest In Nation


BOSTON, June 1, 2018 /PRNewswire-USNewswire/ -- Diagnoses of skin cancers are higher in Massachusetts than the national average and are even higher on Cape Cod, which has the third highest rate of diagnosis in the nation. Skin cancers are diagnosed at a rate of 4.3 percent nationally. In Massachusetts, the rate of diagnosis is 5 percent - tied for sixth highest in the country. In the Barnstable-Yarmouth Metropolitan Statistical Area (MSA) the rate of diagnosis is 8.6 percent - double the national average. The data comes from the Blue Cross Blue Shield Association's (BCBSA) Health of America Report and is for 2016 (see charts below).

Skin Cancer: Shining a Light on the Facts

"These numbers are obviously alarming," said Dr. Bruce Nash, chief physician executive at Blue Cross Blue Shield of Massachusetts. "We're often ranked as one of the healthiest states in the nation, but we clearly have more work to do to educate residents about the risk of skin cancer, especially on the Cape. We encourage our members to get outside, be active and enjoy the nice weather, but we also want to stress the importance of sun protection, including UV-blocking sunglasses, hats with a brim, and broad spectrum sunscreens with a Sun Protection Factor (SPF) of 15 or higher."

Experts also recommend sunscreens that protect against both UV-A and UV-B rays and do not contain oxybenzene, which has been linked to hormone disruption and allergic skin reactions.

Nationwide, the prevalence of the most dangerous form of skin cancer, melanoma, increased 7 percent over a four-year span. Findings show that the rate of Blue Cross and Blue Shield members living with melanoma more than doubled for men ages 55 through 64. Women 54 and younger have a higher prevalence of diagnosed melanoma than men.

Skin cancer is the most common cancer in the United States: Nearly 9,500 people in the U.S. are diagnosed with it each day, according to the American Academy of Dermatology. By taking the skin cancer diagnosis rate of 4.3 percent of Blue Cross members found in the study and extrapolating it to 216 million privately insured people counted by the U.S. Census Bureau, the BCBSA estimates that nine million privately insured people in the U.S. have skin cancer.

Rank

State

Skin cancer diagnosis rate


Rank

MSA

Skin cancer diagnosis rate

1

Florida

7.1%


1

Sarasota-Bradenton, FL

10.0%

2

Washington, D.C.

5.8%


2

Fort Pierce-Port St. Lucie, FL

9.5%

3

Connecticut

5.6%


3

West Palm Beach-Boca Raton, FL

9.5%

4

Rhode Island

5.3%


4

Melbourne-Titusville-Palm Bay, FL

8.6%

4

Vermont

5.3%


5

Barnstable-Yarmouth, MA 

8.6%

4

Maryland

5.3%





5

North Carolina

5.2%





6

Massachusetts

5.0%





6

New York

5.0%





The findings are based on medical claims data from the Blue Cross Blue Shield Health IndexSM (BCBS Health Index?), a first-of-its-kind measurement of health for nearly every county in America. It encompasses more than 200 health conditions and identifies those conditions with the greatest impact on the commercially insured population. The BCBS Health Index is powered by de-identified medical claims data from more than 41 million commercially insured members of BCBS companies. The interactive website allows people to view the overall health and top 10 conditions that negatively impact the health of these members at the state and county levels.

The Blue Cross Blue Shield: The Health of America Report® is a collaboration between BCBSA and Blue Health Intelligence, which uses a market-leading claims database to uncover key trends and insights into health care affordability and access to care.

About Blue Cross Blue Shield Association
The Blue Cross and Blue Shield Association is a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies that collectively provide health care coverage for one in three Americans. BCBSA provides health care insights through The Health of America Report series and the national BCBS Health Indexsm. For more information on BCBSA and its member companies, please visit BCBS.com. We also encourage you to connect with us on Facebook, check out our videos on YouTube, follow us on Twitter and check out our blog.

About BHI
Blue Health Intelligence (BHI) is the nation's premier resource for data-driven insights about healthcare trends and best practices, promoting healthier lives and more affordable access to safe and effective care. BHI leverages a team of analytics experts and advanced technology, coupled with access to the greatest number of healthcare claims?172 million lives?gathered over 10 years in a safe, HIPAA-compliant, secure database. The resulting conformed, reliable data set has the broadest, deepest pool of integrated medical and pharmacy claims, reflecting medical utilization in every ZIP code. Blue Health Intelligence (BHI) is an Independent Licensee of the Blue Cross Blue Shield Association. BHI is a trade name of Health Intelligence Company, LLC. www.bluehealthintelligence.com.

About Blue Cross Blue Shield of Massachusetts
Blue Cross Blue Shield of Massachusetts (bluecrossma.com) is a community-focused, tax-paying, not?for?profit health plan headquartered in Boston. We're the trusted health plan for more than 25,000 Massachusetts employers and are committed to working with others in a spirit of shared responsibility to make quality health care affordable. Consistent with our corporate promise to always put our 2.8 million members first, we're rated among the nation's best health plans for member satisfaction and quality. Connect with us on FacebookTwitterYouTube, and LinkedIn.

Blue Cross Blue Shield of Massachusetts

SOURCE Blue Cross Blue Shield of Massachusetts


These press releases may also interest you

at 10:45
The "PCR Markets. Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2023 to 2027" report has been added to...

at 10:30
The "Licensing Deals in Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...

at 10:30
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical...

at 10:30
Closed System Transfer Devices Market in terms of revenue was estimated to be worth $1.1 billion in 2024 and is poised to reach $2.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by MarketsandMarketstm. The...

at 10:30
RIVANNA®, a developer of imaging-based medical solutions, names Craig Loomis as senior director of product management. With over 25 years of extensive experience in global product development and commercialization within the healthcare sector, Mr....

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...



News published on and distributed by: